



Pharmaceutical Benefits Advisory Committee

Telephone: (02) 6289 7099
Facsimile: (02) 6289 4175

Address all mail to:
PBAC Secretariat
MDP 952
GPO Box 9848
Canberra ACT 2601

DELETION OF PHARMACEUTICAL BENEFIT ITEMS EFFECTIVE 1 APRIL 2015

Following is the advice of the Pharmaceutical Benefits Advisory Committee concerning the deletion of items from the declaration under subsection 85(2) of the *National Health Act 1953*, with effect from the above date.

<u>Item</u>	<u>PBAC Advice</u>
MIFEPRISTONE	The PBAC recommended listing a composite pack containing mifepristone and misoprostol at its July 2014 meeting. The PBAC noted that the composite pack will replace the current listings of the components.
MISOPROSTOL	

Greg O'Toole
Director, Health Technology Assessment
Pharmaceutical Evaluation Branch
17 March 2015